Iovance Crushes Q2 Guidance: Amtagvi Revenue Hits $91M, Gross Margin Surges to 56%, Fast Track for Sarcoma

What happened

Iovance reported second-quarter 2026 total revenue of approximately $99 million, with U.S. Amtagvi sales reaching $91 million, far exceeding the prior $86–88 million guidance and the base-case scenario from our last deep-value report. Gross margin expanded sharply to 56% from 41% in the first quarter, confirming that post-maintenance manufacturing leverage is taking hold and that fixed-cost absorption is improving as infusions scale. The FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas, strengthening the platform narrative and adding a clear catalyst beyond the current melanoma launch. These results directly counter the two central risks flagged in our prior analysis: failure of treatment-center productivity to convert referrals into infusions and stagnant gross margins that would keep the company dilution-dependent. While one strong quarter doesn’t guarantee sustained execution, this print meaningfully increases confidence that Iovance can grow into its valuation and reduces the probability of a near-term capital raise.

Implication

The deep-value report’s base case of a $350M-plus annualized run rate and 46–48% gross margin now looks conservative; 2Q26 revenue annualizes near $400M and gross margin hit 56%. If 3Q26 delivers similar infusion growth and margin stability above 50%, the bull case of $6.20 per share becomes the base case, and the conviction rating should upgrade from WAIT. However, Europe resubmission timelines and cash burn (still negative at -$72M operating cash flow in 1Q26) remain risks, so position size accordingly. The Fast Track for sarcoma provides pipeline upside, but the real driver stays commercial execution. Monitor next quarter’s revenue and gross margin trend, and if they hold, this becomes a BUY on pullbacks to the low-$4s.

Thesis delta

The thesis is strengthening. Q2 revenue nearly $99M and a 56% gross margin trounced both guidance and our base-case checks, turning the key near-term risk—whether network expansion translates into profitable infusions—into an early proof point. This raises the probability of the bull-case scenario (implied value $6.20) and lowers the bear-case risk, compressing the re-assessment window and supporting a more constructive stance pending sustained execution.